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ABSTRACT
The emergence and spread of extensively drug-resistant tuberculosis (XDR-TB) is a 
serious threat to global health. Therefore, its rapid diagnosis is crucial. The present study 
aimed to characterize mutations conferring resistance to second line drugs (SLDs) within 
multidrug Mycobacterium tuberculosis (MDR-MTB) isolates and to estimate the occurrence 
of XDR-TB in Casablanca, Morocco. A panel of 200 MDR-TB isolates was collected at the 
Pasteur Institute between 2015-2018. Samples were subjected to drug susceptibility testing to 
Ofloxacin (OFX), Kanamycin (KAN) and Amikacin (AMK). The mutational status of gyrA, 
gyrB, rrs, tlyA and eis was assessed by sequencing these target genes. Drug susceptibility 
testing for SLDs showed that among the 200 MDR strains, 20% were resistant to OFX, 2.5% 
to KAN and 1.5% to AMK. Overall, 14.5% of MDR strains harbored mutations in gyrA, 
gyrB, rrs and tlyA genes. From the 40 OFXR isolates, 67.5% had mutations in QRDR of 
gyrA and gyrB genes, the most frequent one being Ala90Val in gyrA gene. Of note, none of 
the isolates harbored simultaneously mutations in gyrA and gyrB genes. In eight out of the 
200 MDR-TB isolates resistant either to KAN or AMK, only 25% had A1401G or Lys89Glu 
change in rrs and tlyA genes respectively. This study is very informative and provides data 
on the alarming rate of fluoroquinolone resistance which warrants the need to implement 
appropriate drug regimens to prevent the emergence and spread of more severe forms of 
Mycobacterium tuberculosis drug resistance.
KEYWORDS: Mycobacterium tuberculosis. XDR-TB. DNA sequencing. Drug susceptibility 
testing. Morocco.
INTRODUCTION
Worldwide, the emergence and spread of multidrug-resistant tuberculosis 
(MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) is a real threat 
to global health1,2. MDR-TB is defined as a TB strain resistant to the two first-line 
anti-TB drugs, namely Rifampicin (RIF) and Isoniazid (INH). XDR-TB is an MDR-
TB resistant to one of the fluoroquinolones (FQs) and one of the three injectable 
second-line drugs (SLDs). XDR-TB emerges mainly because of mismanagement 
of MDR-TB and the erratic use of SLDs3.
Molecular diagnosis of MTB drug resistance has been extensively used during 
the three last decades4. These molecular tools are based on the detection of mutations 
in specific genes of MTB that are associated with resistance to anti TB drugs5.
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Treatment of MDR-TB requires the use of FQs and 
injectable drugs. FQs are broad-spectrum antibacterial 
agents against Mycobacterium tuberculosis exerting 
their bactericidal effects by inhibiting the mycobacterial 
DNA gyrase activity, which prevents bacterial DNA 
from unwinding and replicating6. Mutations in genes 
encoding DNA gyrase subunits gyrA and gyrB are the 
most common mechanisms conveying FQ resistance in 
TB. The most frequent resistance-associated mutations 
occur in a conserved region of the gyrA gene (codons 74 
to 113) and, less frequently, the gyrB gene (codons 461 
to 499), known as the quinolone resistance-determining 
region (QRDR)7,8. 
Injectable drugs, namely Kanamycin (KAN), Amikacin 
(AMK) and Capreomycin (CAP) are antibiotics that inhibit 
protein synthesis7. Mutations at positions 1401, 1402, and 
1484 in the rrs gene encoding 16S rRNA confer cross-
resistance to second-line injectable drugs (AMK, KAN, 
and CAP). Mutations in the tlyA gene, which encodes a 
2’-O-methyltransferase that modifies nucleotides in 16S 
rRNA and 23S rRNA, have been suggested to confer 
isolated resistance of M. tuberculosis to CAP. Finally, 
resistance to KAN is due to substitutions G-37T, C-14T, 
C-12T and G-10A affecting the promoter region of the eis 
gene encoding an aminoglycoside acetyltransferase7,9.
In Morocco, as it is the case in resources limited 
countries, drug resistant testing is mainly based on 
conventional methods, including culture and drug 
susceptibility testing (DST). The latter is widely known 
to be slow and laborious, requiring sequential procedures 
for MTB diagnosis and drug resistance profile analysis10. 
During this time, patients may be treated inappropriately, 
drug resistant strains may emerge or may continue 
to spread, and amplification of resistance is likely to 
occur11. Therefore, rapid diagnosis and identification of 
MDR-TB or XDR-TB strains are prerequisites to the fight 
against TB12.
In Morocco, TB affects more than 28.000 people 
every year. The global incidence of all clinical forms of 
tuberculosis is very high, reaching 107 new cases per 
100  thousand inhabitants yearly, Casablanca being the 
area with the highest incidence of TB (139.8 per 100 
thousand inhabitants annually). According to the last 
resistance survey, the prevalence of DR strains was 1% 
among new cases and 8.7% among patients with a previous 
TB history11.
In the absence of national studies for assessing drug 
resistance and genotyping of resistant isolates in Morocco, 
data are retrieved from sporadic studies on a limited number 
of MTB strains. To date, three reports are available on 
mutations associated with resistance of MTB to SLDs. 
A first preliminary study on mutations within gyrA and 
gyrB genes on MTB isolates from a laboratory collection 
(2003-2007) with a small panel of MDR-TB isolates from 
Morocco was conducted by Chaoui et al.13. Later on, 
Oudghiri et al.11 screened for mutations in gyrA, gyrB, 
rrs, tlyA genes and the eis promoter region, and their 
frequencies within MDR-MTB clinical isolates associated 
with resistance to SLDs, in a large panel of clinical 
isolates from TB patients recruited from 2009 to 2012 in 
Casablanca, the highest TB incidence region in Morocco. 
Finally, another study was performed using MTBDRsl 
commercial genotyping tests on a very restricted number 
of pre-XDR MTB isolates (n=21) mainly from Rabat14. 
The present study was conducted (i) to characterize 
mutations associated with resistance to SLDs in a larger 
panel of MDR MTB isolates, (ii) to detect the possible 
disagreements between genotypic and phenotypic DST 
results and (iii) to estimate the occurrence of pre-XDR 




This study was conducted at the Pasteur Institute 
Mycobacteria Laboratory in Casablanca. From 2015 
to 2018, a total of 200 MDR isolates were assessed for 
resistance to RIF and INH by DST. All strains were 
considered unique, i.e., each strain was collected from a 
different TB patient. All isolates were subjected to DST 
for SLDs, DNA genotyping by PCR and DNA sequencing.
The study protocol was approved by the Ethics 
Committee of Morocco’s Institut Pasteur (IPM2013-P3), 
and written informed consent was obtained from each 
study participant.
Drug susceptibility testing
MTB isolates were obtained from Lowenstein–Jensen 
(L/J) medium and tested for drug susceptibility to OFX, 
KAN and AMK. DST was performed using the proportional 
method. The critical drug concentrations were 2 μg/mL for 
OFX, 30 µg/mL for KAN and 40 μg/mL for AMK14. The 
critical proportion of resistant bacilli necessary to define a 
resistant strain is 1% for the three tested drugs15. 
Mycobacterium tuberculosis crude DNA isolation
Scraped bacterial colonies from L/J medium were 
recovered in 400 μL of distilled water and boiled at 
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100 °C for 10 min. to inactivate bacteria and release the 
mycobacterial DNA16. The latter was immediately used for 
PCR amplification or stored at -20 °C until use.
PCR amplification of gyrA, gyrB, rrs, eis and tlyA 
genes
Target sequences of gyrA, gyrB, rrs, and tlyA genes as 
well as the promoter region of the eis gene were amplified 
by PCR using their corresponding primers (Table 1). 
Amplification reactions were performed in a total volume 
of 25 µL containing 0.5 mM of each primer, 2.5 mM of 
each dNTP, 25 mM MgCl
2
, 1 unit of Hotstar Taq DNA 
polymerase (Invitrogen, SaintAubin, France) and 2 µL of 
crude DNA sample in 1X Taq polymerase buffer.
The reagents mixtures were first denatured at 94 °C 
for 7 min. Thirty-five cycles of PCR were then performed, 
with denaturation at 94 °C for 1 min, annealing at the 
corresponding Tm for 30 s and extension at 72 °C for 30 s. 
At the end of the last cycle, mixtures were incubated at 
72 °C for further 7 min. For each reaction, a positive control 
containing DNA from H37Rv strain, and a negative control 
containing sterile H
2
O instead of template DNA were 
included. Amplicons were visualized after electrophoretic 
fractionation in 1 to 2% agarose gels in 0.5 X TBE buffer 
and staining with ethidium bromide.
DNA sequencing
Amplified fragments were firstly purified using the 
illustra ExoProStar 1-Step (GE Healthcare Life Sciences). 
Direct sequencing of amplicons was performed using the 
Big Dye Terminator Kit (version 3.1, Applied Biosystem, 
Foster City, CA, USA) that includes dideoxynucleotides 
labeled with four different fluorochromes. For each PCR 
product, both strands were sequenced in independent 
reactions, using the mentioned primers. The resulting 
chromatograms were manually edited to ensure sequence 
accuracy and analyzed using the Molecular Evolutionary 
Genetics Analysis (MEGA) software (version 5, Center 
for Evolutionary Functional Genomics, Tempe, AZ, USA). 
RESULTS
According to demographic data, the mean age of patients 
was 35 (SD: 11.7), with extreme ages of 14 and 80 years old. 
Of note, 90% of MDR-TB patients were in the age group 
of 20-50 years old, with a male to female sex ratio of 3.3:1. 
Patients were clinically categorized according to WHO 
guidelines; 7.5% of MDR-TB patients were new cases 
(15/200), 10.5% had treatment failure (21/200), 64.5% 
relapsed (129/200) and 17.5% of patients were under 
treatment after loss to follow-up (35/200).
Surprisingly, MDR TB occurred in 7.5% of newly 
diagnosed cases meaning that the corresponding patients 
had a primary resistance. In Morocco, the last national 
surveillance study reported that drug resistance occurred 
rarely among new cases (1%)11. Hence, the difference could 
be due to a sampling bias.
Drug susceptibility testing
Data of DST for SLDs showed that among the 200 MDR 
studied strains, 20% were resistant to OFX (40/200), 2.5% 
to KAN (5/200) and 1.5% to AMK (3/200). Of particular 
interest, five isolates were XDR-MTB, three were resistant 
to OFX and KAN (1.5%) and two were resistant to OFX 
and AMK (1%).
Table 1 - Primers for PCR amplifications.




gyrA For 5’-TGACATCGAGCAGGAGATGC-3’ 320 59
gyrA Rev 5’-GGGCTTCGGTGTACCTCATC-3’
gyrB
gyrB For 5’-GTGGAAATATGTTGGCCGTC-3’ 413 58
gyrA Rev 5’-GTCGTTGTGAACAACGCTGTG-3
rrs
rrs For 5’-GTAATCGCAGATCAGCAACG-3’ 216 58
rrs Rev 5’-GTGATCCAGCCGCACCTT-3’
Eis promotor
eis p For 5’-AAATTCGTCGCTGATTCTCG-3’ 387 56
eis p Rev 5’-CGCGACGAAACTGAGACC-3’
tlyA
tlyA For 5’-GTCTCTGGCCGAACTCGAAG-3’ 1,000 52
tlyA Rev 5’-ATTGTCGCCCAATACTTTTTCTAC-3’
bp = base pairs. 
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The correlation between DST results and clinical 
features showed that almost all resistant isolates to SLDs 
belonged to relapsed, chronicle or treatment failure cases. 
It is also noteworthy that among the 200 MDR-TB strains, 
two new cases had pre-XDR (MDR and OFXR) phenotype.
Genotypic results
Genotypic analysis of gyrA, gyrB, rrs, tlyA genes and the 
eis gene promoter was performed on all MDR strains and 
results are reported in Table 2. Overall, 15.5% of MDR-TB 
strains harbored mutations in gyrA, gyrB, rrs and/or tlyA 
genes conferring resistance to SLDs (31/200). Mutations in 
QRDR regions of gyrA or gyrB genes, conferring resistance 
to FQs, were found in 29 cases, with the most frequent one 
being Ala90Val in gyrA gene observed in 48.8% of isolates 
(14/29). Other point mutations were also found in gyrA 
gene: Asp94Gly in 10.3% (3/29) strains, Asp94Ala and 
Asp94His in four strains each (13.8%). Mutations in gyrB 
gene were reported in four cases and affected exclusively 
the codon 472, with two types of substitutions occurring in 
codon 472 of gyrB gene, namely the Asp/His (3 cases) or 
Asp/Asn (one case). Of note, none of the isolates harbored 
simultaneously mutations in gyrA and gyrB genes.
The correlation between conventional DST and 
molecular genotyping to detect FQs resistance was 
performed and results are reported in Table 3. Accordingly, 
among the 40 phenotypically resistant strains, only 27 
had mutations in QRDR regions of gyrA or gyrB genes. 
Moreover, two strains phenotypically FQ-sensitive harbored 
mutations in gyrA gene.
Depending on these results, specificity and sensitivity 
of the molecular resistance genotyping of FQs to the 
conventional DST were calculated for the recruited MDR 
strains, giving a sensitivity of 67.5% and a specificity of 
86.7 %.
The molecular analysis showed that among the 
200  MDR strains, two strains had mutations in genes 
conferring resistance to injectable drugs; one strain had an 
A/G point mutation in tlyA gene (lys89Glu) and the other 
had A1401G polymorphism in the rrs gene (Table 2), these 
two strains are phenotypically resistant to KAN and AMK, 
respectively.
Other mutations considered as genetic polymorphisms 
and known not to be associated with drug resistance 
were also reported, these SNPs occurred at the codon 95 
(Ser95Thr) of gyrA gene and at position 33 (A/G) of tlyA 
gene (Table 4).
DISCUSSION
The emergence of pre-extensively and extensively 
drug-resistant tuberculosis (Pre-XDR/XDR-TB) among 
MDR-TB isolates represents a serious hurdle for TB 












Codon 90 GCG → GTG Ala / Val 14
25
Codon 94
GAC → GCC Asp / Ala 4
GAC → GGC Asp / Gly 3
GAC → CAC Asp / His 4
gyrB
Codon 472 GAC → CAC Asp / His 3
4
Codon 472 GAC → AAC Asp / Asn 1
Aminosides /cyclic 
peptides
rrs N1401 SNP A/G – 1 1
tlyA Codon 89 AAA → GAA Lys / Glu 1 1
eis – – – – –
Table 3 - Correlation between phenotypic and genotypic results for OFX resistance.






Presence of resistance 
associated mutations
27 2 29
Absence of resistance 
associated mutations
13 158 171
Total 40 160 200
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control programs especially in developing countries2. 
Rapid and efficient methods for the timely detection of 
drug resistance are therefore highly in demand. Within 
this context, we investigated 200 MDR MTB isolates to 
evaluate resistance to SLDs and to identify the main genetic 
mutations associated with drug resistance in Casablanca, 
which includes almost one-fifth of the total TB cases 
recorded in Morocco. 
Mutations in DNA gyrase conferring resistance to 
quinolones have been extensively studied7,8,13. Several 
reports mentioned that most FQs-resistant MTB isolates 
had mutations in the QRDR of DNA gyrase, which is 
the case of the present study, as 67.5% of phenotypically 
OFX-resistant isolates were found to harbor mutations 
in gyrA or gyrB genes. Our results showed that Ala90Val 
was the most predominant substitution (52.2%; 12/23) in 
contrast to previous studies reporting the predominance 
of Asp94Gly (25%)14, Ala90Thr (50%)13 and Asp94Ala 
(67.6%) substitutions11.
Likewise, 27.5% of phenotypically FQs-resistant 
isolates harbored different substitutions in codon 94 of 
the gyrA gene, with substitutions Asp/Ala found in 10%, 
Asp/Gly in 7.5% and Asp/His in 10% of phenotypically 
FQs-resistant isolates. Supporting these data, a systematic 
review by Avalos et al.17 on FQ-resistance mutations 
reported that Asp94Gly and Ala90Val substitutions in 
the gyrA gene were found in 21–32% and 13–20% of 
FQR isolates, respectively. Point mutations at codons 90, 
91, and 94 in the gyrA gene were also found in 54% of 
FQ-resistant MTB strains in a previous study18. Of note, 
our data have further shown that Ser95Thr substitution in 
the gyrA gene was found in 1.5% of MDR-TB isolates, 
indicating that the corresponding strains belong to the 
Principal Genetic Group 1/2 of the M. tuberculosis 
complex19.
In Mycobacterium tuberculosis, gyrB mutations confer 
resistance to FQs both individually and through interactions 
with gyrA mutations. In the present investigation, 
mutations in the gyrB gene were less commonly found 
in OFX-resistant isolates as they occured in only 10% of 
OFX-resistant isolates with mutations detected in codon 472 
of the gyrB gene. Indeed, gyrA substitutions, are much more 
common and generally confer higher levels of resistance 
than those in gyrB. As a result, the dose and duration of 
treatment are impacted by the difference of FQs-resistance 
levels20. However, the inclusion of gyrB mutations increased 
the sensitivity of genotypic FQ resistance from 67.5% to 
77.14% in the present study; 32.5% of FQ-resistant strains 
(13/40) lack mutations in both gyrA and gyrB genes. It 
was reported that the percentage of strains lacking known 
mutations in the QRDR of gyrA or gyrB or both, varied 
from 0 to 60%, which unlikely compromises the sensitivity 
and specificity of molecular testing methods21. Molecular 
techniques to detect resistance mutations lack sensitivity as 
they do not allow to detect all phenotypically FQs-resistant 
strains due to the hetero resistance of mycobacteria22. Also, 
alternative FQs resistance mechanisms such as efflux pumps 
may occur8,11.
Although the sensitivity of molecular diagnosis based 
on gyrA mutations reaches 95%, it may suffer from the 
geographic variability of gyrA mutations distribution. In 
fact, geographic differences in gyrA mutations across the 
globe have been well documented, varying from 3% in Iran 
to 95% in Morocco13,17,23-25.
Furthermore, disagreements between genotypic and 
phenotypic DST were observed in 1% of phenotypically 
OFXS (2/200) harboring mutations in codon 90 of the 
gyrA gene probably due to MIC values close to the critical 
concentration used to define routine resistance to FQs with 
DST and thus not detected by phenotypic testing.
There is a growing evidence that the quite high 
prevalence of FQ resistance in Morocco within MDR MTB 
isolates can be attributed to its previous use for treating other 
infectious diseases11. Indeed, FQs have been extensively 
used to treat a range of infections especially pneumonia26. 
As such, FQ resistance became a major problem worldwide. 
Hence, in a setting of undiagnosed TB, drug-resistant MTB 
mutants may arise and are likely to be selected during FQ-
based treatment of other infections27,28.
In contrast to FQs resistance, resistance to injectable 
drugs has occurred less frequently, since only few strains 
exhibited a resistant status in our study (4%; 8/200). The 
target gene sequencing of rrs, tlyA and eis genes showed that 
only two substitutions were detected: A1401G and lys89Glu 
in rrs and tlyA genes, respectively, each found in one case. In 
the present study, A1401G SNP in rrs gene was associated 
with resistance to AMK. This SNP is common in rrs gene 
and was reported in several studies to be associated with 
resistance to AMK (56% to 100%), KAN (44% to 84%) 
and CAP (51% to 96%)8,29-32. Cross-resistance to second-
Table 4 - Frequency of mutations associated with gene polymorphism in MDR TB isolates.
ATB drug Gene Position Substitution Amino acid change Number of isolates
FQs gyrA Codon 95 AGC → ACC Ser / Thr 3
Aminosides tlyA Position 33 A/G – 10
Momen et al.
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line injectable drugs (AMK, KAN and CAP) is now well 
documented. In fact, mutations at positions 1401 (A/G) 
displays CAP resistance along with high-level resistance 
to AMK and KAN, 1402 (C/T) substitution displays low-
level resistance to KAN and high-level resistance to CAP, 
whereas 1484 (G/T) change displays high-level resistance 
to all three drugs33,34. 
CAP resistance may arise as a result of the lack of 
2’-O-methyltransferase, encoded by the tlyA gene. Previous 
reports revealed that tlyA substitutions were found only in 
CAPR isolates and the corresponding strains were reported 
to exhibit a high level of resistance to this antibiotic35. In 
the present investigation, the tlyA substitution Lys89Glu 
was observed in one MDR OFXR isolate but its sensitivity/
resistance towards CAP was unknown because the latter 
was not available for DST. The Lys89Glu is an infrequent 
mutation that is associated with CAP resistance and was 
described in one previous report35. Overall, mutations in 
the tlyA gene associated with CAP resistance were reported 
to be scarce (∼ 0 to 3% of resistant strains)36. However, 
when reported, mutations in the tlyA gene were not found 
in any CAPS strains, making them highly specific markers 
of CAP resistance30.
It is noteworthy that 5% of tested strains had the A33G 
substitution without any amino acid change, a SNP known 
not to be associated with a resistant genotype13.
Mutations in the eis promoter region were reported to be 
largely associated with KAN resistance30,37. In the present 
study, none of the SNP known to be associated with KAN 
resistance in the eis promoter region was found. Therefore, 
no conclusion could be drawn regarding the frequencies 
of SNPs within the eis promotor gene, due to the small 
number of strains resistant to KAN in our sample. However, 
previous studies reported the occurrence of several SNPs, 
namely, G-10A, C-12T, C-14T in both KAN and AMK 
sensitive and resistant strains5,37. Being very common, 
the SNPs within the eis promotor region are non-specific 
markers of KAN and/or AMK resistance38.
From a molecular point of view, resistance to injectable 
drugs is very tricky to interpret. Indeed, a single mutation, 
or even a set of mutations in a single gene is insufficient 
to predict resistance to AMK, KAN and CAP. It is likely 
that a combination of different gene mutations for each of 
the injectable drugs could better predict the phenotypic 
resistance and promptly guide drug regimens30.
In large scale, early detection of second line anti-TB 
drugs resistance is crucial to timely adjust the treatment 
regimen of MDR-TB and to reduce Pre-XDR and XDR-TB 
strains transmission. The inability to perform DST for SLDs 
is partly responsible for the misuse of anti-tuberculous drugs 
in several countries39. This is not the case in Morocco, as 
routine second-line anti-TB drug susceptibility testing of 
MDR isolates has been included in the diagnostic algorithm 
since 201511. Previous reports along with results from this 
study have clearly demonstrated that resistance to SLDs 
in Morocco is mostly driven by mutations within the gyrA 
gene (codons 90-94) linked to FQ resistance, generating 
thus pre-XDR TB.
CONCLUSION
This study is informative and provides data on genetic 
mutations associated with SLDs resistance in Casablanca, 
a high incidence area for TB. To the best of our knowledge, 
this is the first report describing mutations associated with 
SLDs resistance in a large panel of MDR-MTB isolates 
from Casablanca, the region with the highest incidence of 
TB in Morocco. The findings corroborate preexisting data 
on an alarming rate of FQs resistance, which warrants the 
need to timely detect FQ resistant strains and to implement 
appropriate drug regimens through the prescription of 
alternative and/or additional ATBs. Also, the introduction 
of newer generation of FQs is crucial for successful 
treatment of drug resistant TB to improve treatment 
outcomes for patients with MDR-TB and to prevent the 
emergence, as well as the spread of more severe forms of 
drug resistance. 
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